<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951756</url>
  </required_header>
  <id_info>
    <org_study_id>DK83981</org_study_id>
    <secondary_id>UH2DK083981</secondary_id>
    <nct_id>NCT00951756</nct_id>
  </id_info>
  <brief_title>Controlled Feeding Experiment</brief_title>
  <acronym>CaFE</acronym>
  <official_title>Controlled Feeding Experiment of High and Low Fat Diet and Stool Microbiome Controlled Feeding Experiment of High and Low Fat Diet and Stool Microbiome Composition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James Lewis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of dietary fat, in standard formulation,&#xD;
      on the composition of the human microbiome in a prospective study of normal volunteers.&#xD;
      Participants will be randomly assigned to either a high fat or low fat diet for 10 days. The&#xD;
      gut microbiome will be phylotyped in fecal samples as well as in bacteria adherent to the&#xD;
      colonic mucosa prior to, and during the course of the dietary interventions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This is not an efficacy study. There is no pre-specified clinical endpoint for this study. Rather, the outcome is the composition of the gut microbiome.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Effect of Diet on Microbiome Composition</condition>
  <arm_group>
    <arm_group_label>High Fat Low Fiber Diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Fat High Fiber Diet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High fat diet</intervention_name>
    <description>High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.</description>
    <arm_group_label>High Fat Low Fiber Diet</arm_group_label>
    <arm_group_label>Low Fat High Fiber Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant is capable of giving informed consent&#xD;
&#xD;
          2. Participant is age 18 to 40 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis with Inflammatory bowel disease (IBD), celiac disease, or other chronic&#xD;
             intestinal disorders.&#xD;
&#xD;
          2. Baseline bowel frequency less than every 2 days or greater than 3 times daily.&#xD;
&#xD;
          3. Current smoker.&#xD;
&#xD;
          4. Body Mass Index (BMI) &lt;18.5 of &gt;35.&#xD;
&#xD;
          5. Diabetes mellitus (DM)&#xD;
&#xD;
          6. Diagnosis with coronary artery disease, congestive heart failure, or prior myocardial&#xD;
             infarction.&#xD;
&#xD;
          7. History of dyslipidemia or receiving treatment for hypercholesterolemia. This will be&#xD;
             defined as a fasting LDL &gt;160 mg/dL or a non-fasting total cholesterol &gt;200 mg/dL or&#xD;
             non-fasting HDL&lt;40 mg/dl. Additionally, patients receiving drug therapy for&#xD;
             hypercholesterolemia will be excluded.&#xD;
&#xD;
          8. Prior bowel resection surgery.&#xD;
&#xD;
          9. Contraindication to flexible sigmoidoscopy and biopsies. Patients with suppressed&#xD;
             white blood count may be at increased risk of systemic infection following&#xD;
             sigmoidoscopy with biopsies. As such, subjects with a white blood cell (WBC) count&#xD;
             less than 3,500 or an absolute neutrophil count of less than 1,000 will be excluded.&#xD;
             Patients with thrombocytopenia or with a coagulopathy may be at increased risk of&#xD;
             bleeding complications after colonoscopic biopsies. As such, patients with a platelet&#xD;
             count of less than 100,000 or an international normalized ratio (INR) greater than 1.2&#xD;
             will be excluded from the study.&#xD;
&#xD;
         10. Student or employee of any one of the investigators.&#xD;
&#xD;
         11. Pregnant women.&#xD;
&#xD;
         12. Use of antibiotics in the prior 6 months.&#xD;
&#xD;
         13. Use of antacids, non-steroidal anti-inflammatory drugs (NSAIDs), or dietary&#xD;
             supplements in the preceding 2 weeks.&#xD;
&#xD;
         14. Use of any of the following medications in the 4 weeks prior to randomization: proton&#xD;
             pump inhibitors (PPI), histamine receptor antagonists, narcotics, tricyclic&#xD;
             antidepressants, anticholinergics (e.g., hyoscamine), metoclopramide, anti-diarrhea&#xD;
             medications, laxatives.&#xD;
&#xD;
         15. HIV infection, AIDS, or other known conditions resulting in immunosuppression.&#xD;
&#xD;
         16. Allergies or intolerance to the components of the study diets.&#xD;
&#xD;
         17. Participant has experienced diarrhea within the two weeks prior to the first&#xD;
             sigmoidoscopy. Diarrhea is defined as a change in bowel habits with an increased&#xD;
             frequency or loose stools such that the stool could not be lifted with a fork.&#xD;
&#xD;
         18. Any condition that the investigator feels may limit the volunteer's ability to&#xD;
             complete the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D Lewis, MD, MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>June 22, 2013</last_update_submitted>
  <last_update_submitted_qc>June 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>James Lewis</investigator_full_name>
    <investigator_title>Professor of Medicine and Epidemiology</investigator_title>
  </responsible_party>
  <keyword>Dietary fat</keyword>
  <keyword>Microbiome composition</keyword>
  <keyword>Controlled feeding experiment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

